The Chalice Mining Ltd (ASX: CHN) share price is in focus after the company announced an independent review confirming its prudent environmental approvals pathway for the Gonneville Project, keeping it on track for a Final Investment Decision (FID) in the first half of calendar year 2028.

What did Chalice Mining report?

• Independent Expert Review of Gonneville’s environmental approvals strategy completed by Dr Tom Hatton, former WA EPA Chair
• The review found key risks and mitigation measures are appropriately identified and in place or planned
• Strong engagement with State and Commonwealth regulators, Traditional Owners, and stakeholders highlighted
• The Project retains ‘priority status’ with both the WA and federal governments
• Chalice is targeting a Final Investment Decision for Gonneville in H1 CY28

What else do investors need to know?

Chalice Mining is progressing environmental approvals alongside development studies, execution readiness, and financing activities. This parallel approach aims to keep Gonneville on track as Australia’s next significant critical minerals project.

Environmental modelling for the site has recently been completed, and the company is preparing to submit Environment Review Documents in Q4 2026. The review highlighted Chalice’s comprehensive stakeholder engagement and recognised the company’s transparent and thorough approach to risk management.

What did Chalice Mining management say?

Chalice Mining Managing Director & CEO Alex Dorsch said:

Dr Hatton’s assessment provides confidence in Gonneville’s approvals pathway and our targeted timeline towards a Final Investment Decision in the first half of 2028. Importantly, the review confirms that we have identified the key regulatory processes and risks that could affect the approvals schedule and are taking appropriate steps to address them.

A significant amount of technical, environmental and stakeholder work is already underway, supported by experienced specialist advisers and extensive engagement with State and Commonwealth regulators, Traditional Owners and the local community. Environmental modelling was recently completed ahead of submission of Environment Review Documents (ERDs) in Q4 2026.

Ministerial approval remains on the critical path for Gonneville and this review confirms our target of FID in H1 CY28 is achievable. We remain focused on progressing through the approvals process with the rigour required for a project of this scale and significance.

What’s next for Chalice Mining?

The company is aiming for ministerial approval and timely completion of the environmental approvals process, which is critical for Gonneville’s development. With a plan to reach a Final Investment Decision in the first half of 2028, Chalice is continuing technical studies, stakeholder engagement, and government liaison.

Investors can expect further updates as environmental submissions progress and regulatory milestones are met over the next two years. The management emphasis remains on thorough preparation and collaboration to deliver the Gonneville Project as a leading player in Australia’s critical minerals push.

Chalice Mining share price snapshot

Over the past 12 months, Chalice Mining shares have declined 17%, trailing the All Ordinaries Index (ASX: XAO), which has risen 1% over the same period.

View Original Announcement

The post Chalice Mining: Expert review supports Gonneville timeline appeared first on The Motley Fool Australia.

More reading

• After rocketing 24% last week, what are experts saying about these red hot ASX shares?
• Chalice Mining advances Gonneville, holds $59m cash at June 2026

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

With the gold price booming again, now could be a good time to buy the ASX 200 gold stock in this article.

This is especially the case after a “transformational” year according to the team at Bell Potter.

Which ASX 200 gold stock?

The stock in question is Alkane Resources Ltd (ASX: ALK).

Bell Potter was impressed with the company’s performance in FY 2026, highlighting that it delivered record results and growth across all key metrics. It said:

ALK reported an FY26 financial result that delivered record results and substantial YoY growth across all key financial metrics, together with a maiden dividend of 2cps. This followed the merger with Mandalay Resources (MND:TSX), completed in August 2025 and consecutive quarters of record production from the combined portfolio. Key metrics included revenue of $936m (vs BPe $946m), EBITDA of $471m (vs BPe $473m), and NPAT $229m (vs BPe $238m). 

The maiden dividend of 2cps ($27m payout) was accompanied by the announcement of a share buyback of up to $50m, in a further commitment to returning capital to shareholders and a signal on the value ALK sees in its paper. EBITDA margins lifted from 36% to 50% YoY on higher gold and antimony prices, as well as the dilution of ALK’s out-of-the-money hedge book. At end FY26, ALK held cash and bullion of $439m (vs $190m at completion of the MND merger) and no drawn bank debt. FY27 guidance was reaffirmed, for 163-177koz at AISC of A$2,900-$3,200/oz, implying steady production and ~5% higher costs YoY.

Time to buy

According to the note, in response to the results, Bell Potter has retained its buy rating on the ASX 200 stock with an improved price target of $2.15.

Based on its current share price of $1.85, this implies potential upside of 16% for investors over the next 12 months.

Commenting on its buy recommendation, Bell Potter said:

EPS changes in this report are: FY27: -3%; FY28: -2% and FY29: -5%, reflecting a lower antimony price, higher CAPEX and D&A over the medium term. We also incorporate a sustainable dividend into our modelled assumptions. ALK offers multi-mine gold and antimony exposure across three attractive jurisdictions with a strong balance sheet and available liquidity that provides a platform for growth. Our Target Price lifts 2% to $2.15/sh. Valuation metrics remain undemanding and we retain our Buy recommendation.

The post This ASX 200 gold stock could be a top buy after a ‘transformational’ year appeared first on The Motley Fool Australia.

More reading

• 8 ASX mining shares hitting 52-week highs today
• Alkane Resources discovers new high-grade gold zone at Costerfield
• Alkane Resources declares maiden dividend and $50m share buy-back after strong FY26

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The PolyNovo Ltd (ASX: PNV) share price is in focus after the company reported full-year revenue growth of 16.1% to $150 million and a positive net profit after tax of $7.3 million, marking another year of operational and financial progress.

What did PolyNovo report?

• Total revenue rose 16.1% to $150.0 million
• Commercial sales climbed 16.7% to $138.4 million (21.3% in constant currency)
• EBITDA increased 8.1% to $12.1 million; underlying EBITDA was up 50.4% to $13.4 million
• Positive NPAT of $7.3 million, impacted by one-off items
• Operating cash flow was $23.1 million and free cash flow reached $9.4 million
• Gross margin was 89.0%, down from 95.6% due to inventory changes

What else do investors need to know?

PolyNovo completed construction of its new manufacturing facility, with validation progressing ahead of the planned transition in FY27. Manufacturing output increased significantly in the second half, supporting greater efficiency and future growth capacity.

The company continued to expand clinical evidence for its NovoSorb® platform beyond burns, with key government-backed clinical trial milestones achieved. PolyNovo also advanced regulatory efforts, with PMA submission activities underway to unlock future reimbursement and market opportunities in the US.

What did PolyNovo management say?

Bruce Peatey, Chief Executive Officer of PolyNovo, said:

FY26 was a year of capability building and strategic alignment. We delivered strong commercial growth, expanded our manufacturing capacity, strengthened our balance sheet and continued to invest in the evidence, products and capabilities that will drive PolyNovo’s next phase of growth. During FY26, we sharpened our strategic focus and aligned the business around three clear priorities: accelerating growth in our core wound care franchise, building the next growth engine for PolyNovo, and establishing the global operating structure required to scale efficiently and consistently. Importantly, we achieved this while generating strong cash flow, strengthening our balance sheet, and continuing to invest in the future of the NovoSorb platform.

What’s next for PolyNovo?

Looking ahead, PolyNovo is focused on execution as it prepares for the next phase of growth. The company expects to ramp up production in its new facility and deliver further commercial expansion of NovoSorb® MTX into new indications and geographies.

Regulatory submissions, especially the planned PMA in the US, are set to play a key role in broadening reimbursement and adoption. A new dedicated business development function will seek out partnerships and licensing opportunities to extend the NovoSorb® platform, aiming to drive sustained growth.

PolyNovo share price snapshot

Over the past 12 months, PolyNovo shares have declined 16%, trailing the All Ordinaries Index (ASX: XAO), which has risen 1% over the same period.

View Original Announcement

The post PolyNovo FY26 earnings: Revenue jumps, profit steady appeared first on The Motley Fool Australia.

More reading

• Down 35% for the year, is it time to buy this beaten-down ASX biotech?

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended PolyNovo. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.